ARROWHEAD PHARMACEUTICALS, INC.

Arrowhead Pharmaceuticals develops RNA interference (RNAi) therapeutics designed to treat severe and intractable diseases by silencing disease-causing genes. The company utilizes its proprietary Targeted RNA Molecule (TRiM) platform to trigger targeted, catalytic gene knockdown across diverse tissue types beyond the liver, including adipose tissue, muscle, pulmonary tissue, and the central nervous system. Arrowhead's primary commercialized product is REDEMPLO (plozasiran), an FDA-approved medicine for adults with familial chylomicronemia syndrome, complemented by a clinical pipeline targeting cardiometabolic, pulmonary, renal, and neurodegenerative disorders. The company serves adult patients suffering from rare and high-prevalence genetic disorders directly and partners with major pharmaceutical companies through licensing and co-development collaborations.

Arrowhead maintains clinical and preclinical drug development programs worldwide, with 18 discovered drug candidates in clinical trials spanning Phase 1 to Phase 3. The company conducts late-stage multi-center clinical trials internationally, holds patent protections across dozens of countries, and is expanding its commercial footprint. The text does not disclose the specific location of the company's corporate headquarters.

Summary of the business section of Arrowhead Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of September 30, 2025, the Company employed 711 full-time employees based at four facilities in the United States, including Pasadena and San Diego, California, and Madison and Verona, Wisconsin.”